• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

表皮生长因子受体 (EGFR) 和血管内皮生长因子受体 (VEGFR) 的分子靶向治疗。

Molecular Targeting of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR).

机构信息

Department of Chemistry, Louisiana State University, Baton Rouge, LA 70803, USA.

School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, USA.

出版信息

Molecules. 2021 Feb 18;26(4):1076. doi: 10.3390/molecules26041076.

DOI:10.3390/molecules26041076
PMID:33670650
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7922143/
Abstract

Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) are two extensively studied membrane-bound receptor tyrosine kinase proteins that are frequently overexpressed in many cancers. As a result, these receptor families constitute attractive targets for imaging and therapeutic applications in the detection and treatment of cancer. This review explores the dynamic structure and structure-function relationships of these two growth factor receptors and their significance as it relates to theranostics of cancer, followed by some of the common inhibition modalities frequently employed to target EGFR and VEGFR, such as tyrosine kinase inhibitors (TKIs), antibodies, nanobodies, and peptides. A summary of the recent advances in molecular imaging techniques, including positron emission tomography (PET), single-photon emission computerized tomography (SPECT), computed tomography (CT), magnetic resonance imaging (MRI), and optical imaging (OI), and in particular, near-IR fluorescence imaging using tetrapyrrolic-based fluorophores, concludes this review.

摘要

表皮生长因子受体(EGFR)和血管内皮生长因子受体(VEGFR)是两种广泛研究的膜结合受体酪氨酸激酶蛋白,它们在许多癌症中经常过表达。因此,这些受体家族成为癌症检测和治疗中成像和治疗应用的有吸引力的靶标。本综述探讨了这两种生长因子受体的动态结构和结构-功能关系及其与癌症治疗学的关系,随后介绍了一些常用于靶向 EGFR 和 VEGFR 的常见抑制模式,如酪氨酸激酶抑制剂(TKIs)、抗体、纳米抗体和肽。本文还总结了分子成像技术的最新进展,包括正电子发射断层扫描(PET)、单光子发射计算机断层扫描(SPECT)、计算机断层扫描(CT)、磁共振成像(MRI)和光学成像(OI),特别是基于四吡咯的荧光团的近红外荧光成像。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d271/7922143/4af067fb279b/molecules-26-01076-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d271/7922143/9c6711bbc317/molecules-26-01076-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d271/7922143/cc74fed047a3/molecules-26-01076-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d271/7922143/5f0ed70e216f/molecules-26-01076-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d271/7922143/7e7fca182d88/molecules-26-01076-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d271/7922143/ea84b21a045b/molecules-26-01076-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d271/7922143/5cda5d7cbca1/molecules-26-01076-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d271/7922143/f3e42e870381/molecules-26-01076-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d271/7922143/15bdab55bf28/molecules-26-01076-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d271/7922143/4af067fb279b/molecules-26-01076-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d271/7922143/9c6711bbc317/molecules-26-01076-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d271/7922143/cc74fed047a3/molecules-26-01076-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d271/7922143/5f0ed70e216f/molecules-26-01076-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d271/7922143/7e7fca182d88/molecules-26-01076-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d271/7922143/ea84b21a045b/molecules-26-01076-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d271/7922143/5cda5d7cbca1/molecules-26-01076-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d271/7922143/f3e42e870381/molecules-26-01076-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d271/7922143/15bdab55bf28/molecules-26-01076-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d271/7922143/4af067fb279b/molecules-26-01076-g009.jpg

相似文献

1
Molecular Targeting of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR).表皮生长因子受体 (EGFR) 和血管内皮生长因子受体 (VEGFR) 的分子靶向治疗。
Molecules. 2021 Feb 18;26(4):1076. doi: 10.3390/molecules26041076.
2
Pyrrolo[2,3-D]Pyrimidines as EGFR and VEGFR Kinase Inhibitors: A Comprehensive SAR Review.吡咯并[2,3-d]嘧啶作为 EGFR 和 VEGFR 激酶抑制剂:全面的 SAR 综述。
Curr Med Chem. 2024;31(36):5918-5936. doi: 10.2174/0929867331666230815115111.
3
Gallocin-derived Engineered Peptides Targeting EGFR and VEGFR in Colorectal Cancer: A Bioinformatic Approach.基于蜂毒素的靶向 EGFR 和 VEGFR 的工程化肽在结直肠癌中的应用:一种生物信息学方法。
Curr Top Med Chem. 2024;24(18):1599-1614. doi: 10.2174/0115680266295587240522050712.
4
Recent advances in small molecule inhibitors of VEGFR and EGFR signaling pathways.近年来血管内皮生长因子受体(VEGFR)和表皮生长因子受体(EGFR)信号通路小分子抑制剂的研究进展。
Curr Top Med Chem. 2011;11(12):1571-90. doi: 10.2174/156802611795860924.
5
A tyrosine kinase inhibitor-based high-affinity PET radiopharmaceutical targets vascular endothelial growth factor receptor.一种基于酪氨酸激酶抑制剂的高亲和力正电子发射断层显像(PET)放射性药物靶向血管内皮生长因子受体。
J Nucl Med. 2014 Sep;55(9):1525-31. doi: 10.2967/jnumed.114.138925. Epub 2014 Jun 26.
6
From Tumor to Bone: Growth Factor Receptors as Key Players in Cancer Metastasis.从肿瘤到骨骼:生长因子受体在癌症转移中扮演关键角色
Front Biosci (Landmark Ed). 2024 May 13;29(5):184. doi: 10.31083/j.fbl2905184.
7
Multimodality imaging of vascular endothelial growth factor and vascular endothelial growth factor receptor expression.血管内皮生长因子和血管内皮生长因子受体表达的多模态成像
Front Biosci. 2007 May 1;12:4267-79. doi: 10.2741/2386.
8
[Current Status and Progress in Molecular Imaging of Non-small Cell Lung 
Cancer for Molecular Targeted EGFR-TKI Treatment Sensitivity and 
Treatment Tolerance Prediction].[非小细胞肺癌分子成像在分子靶向EGFR-TKI治疗敏感性及治疗耐受性预测中的现状与进展]
Zhongguo Fei Ai Za Zhi. 2017 Dec 20;20(12):852-856. doi: 10.3779/j.issn.1009-3419.2017.12.10.
9
AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.AEE788:一种双靶点的表皮生长因子受体/ErbB2及血管内皮生长因子受体酪氨酸激酶抑制剂,具有抗肿瘤和抗血管生成活性。
Cancer Res. 2004 Jul 15;64(14):4931-41. doi: 10.1158/0008-5472.CAN-03-3681.
10
Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathways.用于乳腺癌的新一代分子靶向药物:聚焦于表皮生长因子受体(EGFR)和血管内皮生长因子受体(VEGFR)通路
Breast Cancer. 2007;14(2):132-49. doi: 10.2325/jbcs.977.

引用本文的文献

1
The Transcription Machinery and the Driving Force of the Transcriptional Molecular Condensate: The Role of Phosphates.转录机制与转录分子凝聚物的驱动力:磷酸盐的作用
Curr Issues Mol Biol. 2025 Jul 20;47(7):571. doi: 10.3390/cimb47070571.
2
In Vitro and In Silico Wound-Healing Activity of Two Cationic Peptides Derived from Cecropin D in .来源于天蚕素D的两种阳离子肽在体外和计算机模拟中的伤口愈合活性 。 (你提供的原文似乎不完整,最后的“in.”后面应该还有内容)
Antibiotics (Basel). 2025 Jun 27;14(7):651. doi: 10.3390/antibiotics14070651.
3
Advances in Molecular Imaging of VEGFRs: Innovations in Imaging and Therapeutics.

本文引用的文献

1
Click Conjugation of Boron Dipyrromethene (BODIPY) Fluorophores to EGFR-Targeting Linear and Cyclic Peptides.硼二吡咯亚甲基(BODIPY)荧光团点击偶联到 EGFR 靶向线性和环状肽。
Molecules. 2021 Jan 23;26(3):593. doi: 10.3390/molecules26030593.
2
Synthesis, Tumor Specificity, and Photosensitizing Efficacy of Erlotinib-Conjugated Chlorins and Bacteriochlorins: Identification of a Highly Effective Candidate for Photodynamic Therapy of Cancer.埃罗替尼偶联叶绿素和细菌叶绿素的合成、肿瘤特异性和光动力疗效:鉴定一种用于癌症光动力治疗的高效候选药物。
J Med Chem. 2021 Jan 14;64(1):741-767. doi: 10.1021/acs.jmedchem.0c01735. Epub 2021 Jan 5.
3
血管内皮生长因子受体的分子成像进展:成像与治疗的创新
Int J Mol Sci. 2025 Jun 4;26(11):5373. doi: 10.3390/ijms26115373.
4
Targeting endothelial growth factor receptor in thyroid cancer: current concepts and future directions.甲状腺癌中内皮生长因子受体的靶向治疗:当前概念与未来方向
Med Oncol. 2025 Jun 2;42(7):233. doi: 10.1007/s12032-025-02788-0.
5
Targeting vascular endothelial growth receptor-2 (VEGFR-2): structural biology, functional insights, and therapeutic resistance.靶向血管内皮生长因子受体-2(VEGFR-2):结构生物学、功能见解及治疗抗性
Arch Pharm Res. 2025 May 8. doi: 10.1007/s12272-025-01545-1.
6
Colorectal Cancer: Risk Factors, Novel Approaches in Molecular Screening and Treatment.结直肠癌:风险因素、分子筛查与治疗的新方法
Int J Mol Cell Med. 2025;14(1):576-605. doi: 10.22088/IJMCM.BUMS.14.1.576.
7
Experimental and Computational Investigation of Cu(II) and Zn(II) complexes: DFT, Docking, and Anti-Lung Cancer Studies.铜(II)和锌(II)配合物的实验与计算研究:密度泛函理论、对接及抗肺癌研究
Future Med Chem. 2025 Mar;17(6):669-679. doi: 10.1080/17568919.2025.2478815. Epub 2025 Mar 21.
8
Surface Functionalization of Nanocarriers with Anti-EGFR Ligands for Cancer Active Targeting.用于癌症主动靶向的抗表皮生长因子受体(EGFR)配体修饰纳米载体的表面功能化
Nanomaterials (Basel). 2025 Jan 21;15(3):158. doi: 10.3390/nano15030158.
9
Dual VEGFR-2 and EGFR inhibitors of phenyldiazenes: anticancer evaluations, ADMET, docking, design and synthesis.苯基重氮化合物的双 VEGFR-2 和 EGFR 抑制剂:抗癌评估、ADMET、对接、设计与合成
Future Med Chem. 2025 Feb;17(3):287-300. doi: 10.1080/17568919.2025.2453409. Epub 2025 Jan 17.
10
Radiopharmaceuticals and their applications in medicine.放射性药物及其在医学中的应用。
Signal Transduct Target Ther. 2025 Jan 3;10(1):1. doi: 10.1038/s41392-024-02041-6.
EGFR-Binding Peptides: From Computational Design towards Tumor-Targeting of Adeno-Associated Virus Capsids.
EGFR 结合肽:从计算设计到腺相关病毒衣壳的肿瘤靶向。
Int J Mol Sci. 2020 Dec 15;21(24):9535. doi: 10.3390/ijms21249535.
4
Targeted nanobody complex enhanced photodynamic therapy for lung cancer by overcoming tumor microenvironment.靶向纳米抗体复合物通过克服肿瘤微环境增强肺癌光动力治疗
Cancer Cell Int. 2020 Nov 27;20(1):570. doi: 10.1186/s12935-020-01613-0.
5
EGFR and anti-EGFR nanobodies: review and update.表皮生长因子受体(EGFR)及其纳米抗体:综述与更新。
J Drug Target. 2021 Apr;29(4):387-402. doi: 10.1080/1061186X.2020.1853756. Epub 2020 Dec 3.
6
Dual Targeting of Endothelial and Cancer Cells Potentiates In Vitro Nanobody-Targeted Photodynamic Therapy.内皮细胞和癌细胞的双重靶向增强了体外纳米抗体靶向光动力疗法。
Cancers (Basel). 2020 Sep 23;12(10):2732. doi: 10.3390/cancers12102732.
7
Anti-EGFR Binding Nanobody Delivery System to Improve the Diagnosis and Treatment of Solid Tumours.抗 EGFR 结合纳米抗体递药系统改善实体瘤的诊断和治疗
Recent Pat Anticancer Drug Discov. 2020;15(3):200-211. doi: 10.2174/1574892815666200904111728.
8
Photo-induced specific intracellular release EGFR inhibitor from enzyme/ROS-dual sensitive nano-platforms for molecular targeted-photodynamic combinational therapy of non-small cell lung cancer.基于酶/ROS 双重敏感纳米平台的光诱导型 EGFR 抑制剂特异性释放用于非小细胞肺癌的分子靶向光动力联合治疗。
J Mater Chem B. 2020 Sep 21;8(35):7931-7940. doi: 10.1039/d0tb01053g. Epub 2020 Aug 11.
9
Targeting EGFR Overexpression at the Surface of Colorectal Cancer Cells by Exploiting Amidated BODIPY-Peptide Conjugates.利用酰胺化 BODIPY-肽缀合物靶向结直肠癌细胞表面的 EGFR 过表达。
Photochem Photobiol. 2020 May;96(3):581-595. doi: 10.1111/php.13234. Epub 2020 Apr 16.
10
PLGA Porous Microspheres Dry Powders for Codelivery of Afatinib-Loaded Solid Lipid Nanoparticles and Paclitaxel: Novel Therapy for EGFR Tyrosine Kinase Inhibitors Resistant Nonsmall Cell Lung Cancer.PLGA 多孔微球干粉共载阿法替尼载药固体脂质纳米粒和紫杉醇:用于治疗 EGFR 酪氨酸激酶抑制剂耐药非小细胞肺癌的新型疗法。
Adv Healthc Mater. 2019 Dec;8(23):e1900965. doi: 10.1002/adhm.201900965. Epub 2019 Oct 30.